Format

Send to

Choose Destination
Gastroenterol Res Pract. 2016;2016:3481578. doi: 10.1155/2016/3481578. Epub 2016 Aug 16.

Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer.

Author information

1
III. Medizinische Klinik, Universitätsmedizin Mannheim, 68167 Mannheim, Germany.
2
Stratifyer Molecular Pathology GmbH, 50935 Köln, Germany.
3
Pathologisches Institut, Universitätsmedizin Mannheim, 68167 Mannheim, Germany.
4
Chirurgische Klinik, Universitätsmedizin Mannheim, 68167 Mannheim, Germany.
5
Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Mannheim, 68167 Mannheim, Germany.
6
Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, 07747 Jena, Germany.
7
Klinik für Urologie, Universitätsmedizin Mannheim, 68167 Mannheim, Germany.

Abstract

BACKGROUND:

No predictive or prognostic biomarker is available for patients with locally advanced rectal cancer (LARC) undergoing perioperative chemoradiotherapy (CRT). Members of the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases EGFR (HER1, ERBB1), HER2 (ERBB2), HER3 (ERBB3), and HER4 (ERBB4) are therapeutic targets in several cancers. The analysis was performed to assess expression levels and study the potential prognostic impact for disease-free and overall survival in patients with LARC.

PATIENTS AND METHODS:

ERBB1-4 mRNA expression and tumor proliferation using Ki-67 (MKI67) mRNA were evaluated using RT-quantitative PCR in paraffin-embedded tumor samples from 86 patients (median age: 63) treated with capecitabine or 5-fluorouracil-based CRT within a phase 3 clinical trial.

RESULTS:

A positive correlation of HER4 and HER2, HER3 and HER2, and HER4 and HER3 with each other was observed. Patients with high mRNA expression of ERBB1 (EGFR, HER1) had significantly increased risk for recurrence and death. Patients with high mRNA expression of MKI67 had reduced risk for relapse.

CONCLUSION:

This analysis suggests a prognostic impact of both ERBB1 and MKi67 mRNA expression in LARC patients treated with capecitabine or fluorouracil-based chemoradiotherapy.

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center